Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study

References

• ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ20048284485115640920
   PubMed Web of Science ®Google Scholar
• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol20069026226716488940
   PubMed Web of Science ®Google Scholar
• SchmidlDSchmettererLGarhöferGPopa-CherecheanuAPharmacotherapy of glaucomaJ Ocul Pharmacol Ther2015312637725587905
   PubMed Web of Science ®Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavonaDogma2008
   Google Scholar
• KomotoJYamadaTWatanabeKWoodwardDFTakusagawaFProstaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprostBiochemistry20064571987199616475787
   PubMed Web of Science ®Google Scholar
• PolanskyJRKurtzRMAlvaradoJAWeinrebRNMitchellMDEicosanoid production and glucocorticoid regulatory mechanisms in cultured human trabecular meshwork cellsProg Clin Biol Res19893121131382508121
   PubMedGoogle Scholar
• MatsumotoSYorioTMagninoPEDeSantisLPangIHEndothelin-induced changes of second messengers in cultured human ciliary muscle cellsInvest Ophthalmol Vis Sci1996376105810668631621
   PubMed Web of Science ®Google Scholar
• Lütjen-DrecollETammEMorphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alphaExp Eye Res19884757617693197775
   PubMed Web of Science ®Google Scholar
• VohraRTsaiJCKolkoMThe role of inflammation in the pathogenesis of glaucomaSurv Ophthalmol201358431132023768921
   PubMed Web of Science ®Google Scholar
• BazanNGAllanGSignal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipidsSurv Ophthalmol199741Suppl 2S23S349154273
   PubMedGoogle Scholar
• ChaoWOlsonMSPlatelet-activating factor: receptors and signal transductionBiochem J19932926176298391253
   PubMed Web of Science ®Google Scholar
• FragopoulouEIatrouCDemopoulosCACharacterization of acetyl-CoA: lyso-PAF acetyltransferase of human mesangial cellsMediators Inflamm20052005526327216258193
   PubMedGoogle Scholar
• McManusLMPinckardRNPAF, a putative mediator of oral inflammationCrit Rev Oral Biol Med200011224025812002818
   PubMedGoogle Scholar
• DerewendaZSDerewendaUThe structure and function of platelet-activating factor acetylhydrolasesCell Mol Life Sci1998544464559645224
   PubMed Web of Science ®Google Scholar
• RosenbaumJTBoneyRSSamplesJRValoneFHSynthesis of platelet activating factor by ocular tissue from inflamed eyesArch Ophthalmol199110934104132003804
   PubMedGoogle Scholar
• TsouprasABChiniMMangafasNPlatelet activating factor and its basic metabolic enzymes in blood of naive HIV-infected patientsAngiology20126334335221948973
   PubMed Web of Science ®Google Scholar
• BradfordMMA rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem197672248254942051
   PubMed Web of Science ®Google Scholar
• AntonopoulouSFragopoulouEKarantonisHCEffect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitusJ Med Food2006935636217004898
   PubMed Web of Science ®Google Scholar
• MoschosMMChatziralliIPStamatakisGPapakonstantinouVDTsatsosMDemopoulosCAIn vitro effects of anti-glaucomatous eye drops on platelet activating factor and its metabolismSemin Ophthalmol Epub2015813
   PubMed Web of Science ®Google Scholar
• TsouprasABFragopoulouENomikosTIatrouCAntonopoulouSDemopoulosCACharacterization of the de novo biosynthetic enzyme of platelet activating factor, DDT insensitive cholinephosphotransferase, of human mesangial cellsMediators Inflamm200720072768317710109
   PubMed Web of Science ®Google Scholar
• TsouprasABChiniMTsogasNAnti-platelet activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?AIDS Res Hum Retroviruses2008241079108618620493
   PubMed Web of Science ®Google Scholar
• GimenezRAguilarJCytidine (5′) diphosphocholine induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged ratsNeurosci Lett200129920921211165772
   PubMed Web of Science ®Google Scholar
• AntonopoulouSDemopoulosCAIatrouCMoustakasGZirogiannisPPlatelet activating factor acetylhydrolase (PAF-AH) in human kidneyInt J Biochem199426115711627988740
   PubMedGoogle Scholar
• OtaTAiharaMNarumiyaSAraieMThe effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient miceInvest Ophthalmol Vis Sci2005464159416316249494
   PubMed Web of Science ®Google Scholar
• WoodwardDFKraussAHChenJPharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024)J Pharmacol Exp Ther2003305277278512606640
   PubMed Web of Science ®Google Scholar
• GandolfiSSimmonsSTSturmRChenKVanDenburghAMBimatoprost Study Group 3Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
   PubMed Web of Science ®Google Scholar
• KonstasAGKatsimbrisJMLallosNBoukarasGPJenkinsJNStewartWCLatanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patientsOphthalmology2005112226226615691561
   PubMed Web of Science ®Google Scholar
• NoeckerRSDirksMSChoplinNTBernsteinPBatoosinghALWhitcupSMBimatoprost/Latanoprost Study GroupA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
   PubMed Web of Science ®Google Scholar
• UusitaloHEgorovEKaarnirantaKAstakhovYRopoABenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsClin Ophthalmol20161044545427041987
   PubMed Web of Science ®Google Scholar
• OtaTAiharaMSaekiTNarumiyaSAraieMThe IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient miceBr J Ophthalmol200791567367617124244
   PubMed Web of Science ®Google Scholar
• KurashimaHWatabeHSatoNAbeSIshidaNYoshitomiTEffects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprostExp Eye Res201091685385920868682
   PubMed Web of Science ®Google Scholar
• YamadaHYonedaMGoshoMKatoTZakoMBimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinasesBMC Ophthalmol2016162626956170
   PubMed Web of Science ®Google Scholar
• JagerGVvan DelftJLvan HaeringenNJVerbeijNLBraquetPAntagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbitsProstaglandins1993451971058424134
   PubMedGoogle Scholar
• ShuklaSDPlatelet-activating factor receptor and signal transduction mechanismsFASEB J19926229623011312046
   PubMed Web of Science ®Google Scholar
• BazanHOttinoPThe role of platelet-activating factor in the corneal response to injuryProg Retin Eye Res20022144946412207945
   PubMed Web of Science ®Google Scholar
• ZhouXLiFKongLTomitaHLiCCaoWInvolvement of inflammation, degradation, and apoptosis in a mouse model of glaucomaJ Biol Chem200528035312403124815985430
   PubMed Web of Science ®Google Scholar